Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.

Conclusion: The findings support ICT in iron-overloaded patients with low- to intermediate-1-risk MDS, with longer EFS compared with placebo and a clinically manageable safety profile. Therefore, ICT may be considered in these patients.
Primary Funding Source: Novartis Pharma AG.
PMID: 32203980 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - March 23, 2020 Category: Internal Medicine Authors: Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G, TELESTO Study Investigators Tags: Ann Intern Med Source Type: research